You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Proteolytic Imaging of Remodeling Myocardium
SBC: Micro Vide, LLC Topic: NHLBIDESCRIPTIONprovided by applicantProteolytic Imaging of Remodeling Myocardium Abstract Heart attacksi emyocardial infarction or MIoccur in more thanmillion patients annuallyAdvances in interventional and pharmacological therapies have dramatically improved survival following the initial MIand patients are often surviving acute MI with more extensive myocardial injuryConsequentlythe number of patien ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
IGF OT IGF IN VITRO CANCER STEM CELL EXPANSION PROGRAM FOR RARE TUMOR TYPES PERIOD OF PERFORMANCE
SBC: KIYATEC, LLC Topic: NCIThe overall objective of this proposal is to develop an in vitro process by which cancer stem cells CSC can be isolated from primary human tumor biopsies or tissues expanded without losing critical elements of stem cell qualities and then used for preclinical and clinical applications During this fast track proposal KIYATEC will employ an integrated functional and unbiased scientific strate ...
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Intelligent Biometrics to Optimize Prolonged Exposure Treatment for PTSD (IB-PE)
SBC: Zeriscope, Inc. Topic: 104PROJECT SUMMARY/ABSTRACT Posttraumatic Stress Disorder (PTSD) is a debilitating disease affecting millions of American military veterans and civilians. Prolonged Exposure (PE) therapy is evidence-based and effective but limited by high dropout rates and incomplete resolution of symptoms in approximately one-third of patients. A crucial component of PE, as well as interventions for anxiety disorder ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples
SBC: CIRCA BIOSCIENCE LLC Topic: 102Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Developing chemoenzymatic strategies, enzymes, and kits for accessible and affordable gangliosides
SBC: Integrated Micro-Chromatography Systems, Inc. Topic: 300Project Summary Gangliosides, analogous to biological antennae in cells, are involved in critical roles across multiple biological processes (i.e. pathogen infection, cell-cell communication, inflammation). Neuroprotective and neurorestorative functions of gangliosides have been explored for their therapeutic application in Parkinson’s disease and other neurodegenerative diseases. Despite such i ...
SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Stroke Treatment by Chemically-Induced Hypothermia
SBC: HALIMED PHARMACEUTICALS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Stroke is the third leading cause of death in the United States. In spite of intensive investigations, clinical therapies for treating acute stroke patients remain limited and unsatisfactory. There are consistent animal and human data that mild to moderate hypothermia (reducing body temperature to 32-34oC) is generally safe and improves outcome after brain ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Delivery of chemically modified PNA oligomers
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARYRNA is a validated target for drug design, both as therapeutic and as a target. Targeting specific RNA, such as rRNA which are involved in proliferation and survival of bacteria is a promising approach. We are developing fast and low cost methods to screen sequence-specific small molecules for novel anti-ribosomal activities. We will construct sequence-specific chemically modified r ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Aminoglycosides with reduced ototoxicity via miRNA targeting
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low cost methods to develop aminoglycosides with anti- ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced o ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
SBC: LEUKOGENE THERAPEUTICS INC Topic: NCIProject Summary/Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Poor survival rates are largely due to the late stage at which PDAC is diagnosed and a lack of effective targeted therapies. While the field of immunotherapy has significantly increased overall survival in some malignancies, they have not translated to PDAC. The long-term goal of this research ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Nucleobase aminosugars with reduced ototoxicity
SBC: NUBAD LLC Topic: YPROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health